New combinations in the treatment of COPD: rationale for aclidinium-formoterol

about

Initiating Titratable Fixed-Ratio Combinations of Basal Insulin Analogs and Glucagon-Like Peptide-1 Receptor Agonists: What You Need to Know.

P2860

Q52568454-F461AA8A-844A-4D1B-B1BF-E7C4ED64E928

P2860

New combinations in the treatment of COPD: rationale for aclidinium-formoterol

Item

http://www.wikidata.org/entity/Q26765303

description

2016 nî lūn-bûn

@nan

2016 թուականին հրատարակուած գիտական յօդուած

@hyw

2016 թվականին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

New combinations in the treatment of COPD: rationale for aclidinium-formoterol

@ast

New combinations in the treatment of COPD: rationale for aclidinium-formoterol

@en

New combinations in the treatment of COPD: rationale for aclidinium-formoterol

@nl

type

Item

label

New combinations in the treatment of COPD: rationale for aclidinium-formoterol

@ast

New combinations in the treatment of COPD: rationale for aclidinium-formoterol

@en

New combinations in the treatment of COPD: rationale for aclidinium-formoterol

@nl

prefLabel

New combinations in the treatment of COPD: rationale for aclidinium-formoterol

@ast

New combinations in the treatment of COPD: rationale for aclidinium-formoterol

@en

New combinations in the treatment of COPD: rationale for aclidinium-formoterol

@nl

P1476

New combinations in the treatment of COPD: rationale for aclidinium-formoterol

@en

P2093

Elena Makri

http://www.w3.org/2001/XMLSchema#string

Marcello Montagni

http://www.w3.org/2001/XMLSchema#string

P2860

Aclidinium bromide for stable chronic obstructive pulmonary disease

Long-acting beta2-agonists for chronic obstructive pulmonary disease

Formoterol versus short-acting beta-agonists as relief medication for adults and children with asthma

Formoterol. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease

The pharmacological properties of tiotropium.

β2-agonist therapy in lung disease.

Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study.

Salmeterol xinafoate. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease.

Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study

Incident pneumonia and mortality in patients with chronic obstructive pulmonary disease. A double effect of inhaled corticosteroids?

P304

209-15

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/TCRM.S82034

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Erminia Ridolo

Cristoforo Incorvaia

P577

2016-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26929634

http://www.w3.org/2001/XMLSchema#string

P932

4760652

http://www.w3.org/2001/XMLSchema#string

New combinations in the treatment of COPD: rationale for aclidinium-formoterol

about

P2860

P2860

New combinations in the treatment of COPD: rationale for aclidinium-formoterol

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P50

P577

P698

P932